Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Textual)

v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
In Millions, unless otherwise specified
3 Months Ended 1 Months Ended
Mar. 31, 2013
Segment
Dec. 31, 2012
Collaborative Arrangement, Co-promotion [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]    
FDA approval milestone payment   $ 50.0
Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract]    
Number of operating business segments 1  
Non-cash loss on an increase in the fair value $ 3.0